INCYTE CORP (INCY) is drawing unusual attention today. Our newswire has captured 4 stories on INCY across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
INCY stock is up 9.30% at $129.93 as of the latest trade, driven by regulatory approval and updated guidance for its key product, Opzelura. The European Commission approved Opzelura as the first steroid-free topical JAK inhibitor for moderate atopic dermatitis in adults. Incyte also raised its 2026 net sales guidance, citing strong performance across its portfolio and a settlement with the Centers for Medicare & Medicaid Services.
The European approval of Opzelura marks a significant expansion for Incyte, providing access to a new market for this JAK inhibitor. This approval follows a recent settlement with CMS that resolved prior reimbursement issues in the U.S. and contributed to an upward revision of Opzelura’s sales guidance to $1.050B, $1.1B. Incyte also reported second-quarter 2026 net product sales of $1.49 billion, a 40% increase from the prior year, and raised its full-year net sales forecast to $5.130B, $5.260B. These developments, combined with positive analyst sentiment, fueled the sharp rise in the stock.
The stock opened at $131.56, a modest gap up from the prior close, but traded in a narrow range throughout the session. Volume remains at 0.0M shares, below the 3-month average. The stock has risen 9.0% over the last 8 sessions, reaching a new 52-week high of $132.60. Incyte’s fundamentals remain strong, with a revenue growth of 21.5% trailing twelve months and a net margin of 26.7%. Recent insider transactions show six sales totaling $5.4M over the last 90 days, with the most recent filing on July 20.
The company’s earnings call presentation for Q2 2026 is available, and further updates on Opzelura’s performance in the EU and U.S. will be key. Coverage breadth and analyst ratings should be monitored, especially as Oppenheimer and HC Wainwright have raised price targets to $120 and $150, respectively.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.
Guggenheim raises Incyte stock price target to $150 on strong results
H.C. Wainwright raises Incyte stock price target to $150 on revenue beat
INCYTE CORP (INCY) is drawing unusual attention today. Our newswire has captured 4 stories on INCY across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100). The most recent driver: "Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod" (Stocktwits News).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of INCY coverage reads 59/100 over 4 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on INCY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier INCY move explainers: 2026-07-29 · 2026-07-28